CN116234569A - 冠状病毒结合剂 - Google Patents

冠状病毒结合剂 Download PDF

Info

Publication number
CN116234569A
CN116234569A CN202180027079.5A CN202180027079A CN116234569A CN 116234569 A CN116234569 A CN 116234569A CN 202180027079 A CN202180027079 A CN 202180027079A CN 116234569 A CN116234569 A CN 116234569A
Authority
CN
China
Prior art keywords
sars
cov
binding
rbd
vhh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027079.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·谢彭斯
X·赛伦斯
N·卡莱外特
D·德夫利格
L·范斯奇
W·尼瑞克斯
K·罗斯
W·范布里丹
H·埃克豪特
D·菲贾尔科夫斯卡
C·洛尼格罗
S·德卡
B·东布雷克特
C·施多瑞乐斯
J·内茨
L·德朗
S·卡普坦
J·杜阿尔特达罗查佩雷拉
B·格雷厄姆
J·麦克莱伦
D·万鹏
H·瑞姆特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elsevier Biotech Co ltd
Lefin Catholic University Office Of Technology Transfer Dutch Language University Of Leuven
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Dartmouth College
University of Texas System
US Department of Health and Human Services
Original Assignee
Elsevier Biotech Co ltd
Lefin Catholic University Office Of Technology Transfer Dutch Language University Of Leuven
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Dartmouth College
University of Texas System
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2020508.4A external-priority patent/GB202020508D0/en
Application filed by Elsevier Biotech Co ltd, Lefin Catholic University Office Of Technology Transfer Dutch Language University Of Leuven, Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Vrije Universiteit Brussel VUB, Dartmouth College, University of Texas System, US Department of Health and Human Services filed Critical Elsevier Biotech Co ltd
Priority claimed from PCT/EP2021/052885 external-priority patent/WO2021156490A2/en
Publication of CN116234569A publication Critical patent/CN116234569A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180027079.5A 2020-02-06 2021-02-05 冠状病毒结合剂 Pending CN116234569A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062971013P 2020-02-06 2020-02-06
US62/971,013 2020-02-06
US202062988610P 2020-03-12 2020-03-12
US62/988,610 2020-03-12
US202062991408P 2020-03-18 2020-03-18
US62/991,408 2020-03-18
US202063041240P 2020-06-19 2020-06-19
US63/041,240 2020-06-19
EPPCT/EP2020/077004 2020-09-25
EPPCT/EP2020/077004 2020-09-25
GBGB2020508.4A GB202020508D0 (en) 2020-12-23 2020-12-23 Multivalent sars-cov-2 virus binders
GB2020508.4 2020-12-23
EP21151356 2021-01-13
EP21151356.9 2021-01-13
PCT/EP2021/052885 WO2021156490A2 (en) 2020-02-06 2021-02-05 Corona virus binders

Publications (1)

Publication Number Publication Date
CN116234569A true CN116234569A (zh) 2023-06-06

Family

ID=83365410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027079.5A Pending CN116234569A (zh) 2020-02-06 2021-02-05 冠状病毒结合剂

Country Status (8)

Country Link
US (1) US20230227537A1 (https=)
EP (1) EP4100055A2 (https=)
JP (1) JP2023516280A (https=)
KR (1) KR20220166787A (https=)
CN (1) CN116234569A (https=)
AU (1) AU2021217563A1 (https=)
CA (1) CA3166967A1 (https=)
IL (1) IL295389A (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115485375A (zh) * 2020-05-11 2022-12-16 莱桑多公司 Ace-2受体的可溶性受体片段的病毒中和作用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
AR123469A1 (es) * 2020-09-10 2022-12-07 Bighat Biosciences Inc DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS
CN113755421B (zh) * 2021-09-28 2024-04-12 梦芊细胞因子有限公司 一种用于covid-19的口服性疫苗及抗体加强剂
JP2024536380A (ja) * 2021-10-07 2024-10-04 セキラス ピーティーワイ リミテッド 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用Ｉ
WO2025033553A1 (ja) * 2023-08-10 2025-02-13 国立大学法人 東京大学 新規なｈｖｅｍ結合タンパク質およびそれを含む医薬組成物
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
JP2008529504A (ja) * 2005-02-08 2008-08-07 ニューヨーク ブラッド センター 重症急性呼吸器症候群関連コロナウイルスに対する中和モノクローナル抗体
CN101522208A (zh) * 2005-02-08 2009-09-02 纽约血库公司 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
US20110182897A1 (en) * 2008-06-05 2011-07-28 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
JP2008529504A (ja) * 2005-02-08 2008-08-07 ニューヨーク ブラッド センター 重症急性呼吸器症候群関連コロナウイルスに対する中和モノクローナル抗体
CN101522208A (zh) * 2005-02-08 2009-09-02 纽约血库公司 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
US20110182897A1 (en) * 2008-06-05 2011-07-28 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
V. STALIN RAJ等: "Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection", SCIENCE ADVANCES, vol. 4, 8 August 2018 (2018-08-08), pages 1 - 10 *
何雷等: "中东呼吸综合征冠状病毒特异性纳米抗体噬菌体展示库的构建和鉴定", 细胞与分子免疫学杂志, vol. 33, no. 12, 28 March 2018 (2018-03-28), pages 1662 - 1668 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115485375A (zh) * 2020-05-11 2022-12-16 莱桑多公司 Ace-2受体的可溶性受体片段的病毒中和作用

Also Published As

Publication number Publication date
JP2023516280A (ja) 2023-04-19
CA3166967A1 (en) 2021-08-12
IL295389A (en) 2022-10-01
KR20220166787A (ko) 2022-12-19
EP4100055A2 (en) 2022-12-14
US20230227537A1 (en) 2023-07-20
AU2021217563A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
WO2021156490A2 (en) Corona virus binders
CN116234569A (zh) 冠状病毒结合剂
IL296224A (en) Antibodies against corona virus and methods of use
KR102557216B1 (ko) 그렘린-1 결정 구조 및 억제 항체
US11028167B1 (en) Anti-SARS-Cov-2 antibodies derived from 3bgf
JP2024506315A (ja) コロナウイルスのスパイクタンパク質を標的とする抗体
US20250313611A1 (en) Sarbecovirus spike s2 subunit binders
CN117794566A (zh) 沙贝病毒结合剂
US20240101647A1 (en) Sarbecovirus binders
KR20240142594A (ko) 코로나바이러스 sars-cov-2의 스파이크 단백질에 결합할 수 있는 항체
EP3992205A1 (en) Sars coronavirus-2 spike protein binding compounds
TW202144406A (zh) ＳＡＲＳ－ＣｏＶ－２抗體及其應用
WO2021194891A1 (en) Anti-sars-cov-2 antibodies derived from cr3022
WO2021194886A1 (en) Anti-sars-cov-2 antibodies derived from 3bgf
WO2021194896A1 (en) Anti-sars-cov-2 antibodies derived from 2ghw
CA3194792A1 (en) Novel anti-a2ap antibodies and uses thereof
WO2021194985A1 (en) Anti-sars-cov-2 antibodies derived from 6nb6
WO2021194951A1 (en) Anti-sars-cov-2 antibodies derived from 2dd8
US20250109186A1 (en) SARS-CoV-2 BINDING PROTEINS AND METHODS OF USE THEREOF
JP2024535249A (ja) 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
EP4651892A2 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
WO2025163490A1 (en) Growth factor receptor agonist/antagonist
CN116406375A (zh) 抗SARS-CoV-2刺突蛋白的三聚体抗体
HK40010475B (zh) Gremlin-1晶体结构和抑制性抗体
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination